Skip Navigation


European Heart Journal Advance Access originally published online on April 12, 2006
European Heart Journal 2006 27(10):1137-1138; doi:10.1093/eurheartj/ehi702
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/10/1137    most recent
ehi702v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Horan, P. G.
Right arrow Articles by McKeown, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horan, P. G.
Right arrow Articles by McKeown, P. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Anthracycline cardiotoxicity

Paul G. Horan1, Mary Frances McMullin2 and Pascal P. McKeown1,3,*

1 Regional Medical Cardiology Centre, Royal Victoria Hospital, Belfast, Northern Ireland, UK
2 Department of Haematology, Queen's University Belfast, Northern Ireland, UK
3 Department of Medicine, Institute of Clinical Science, Queen's University Belfast, Grosvenor Road, Belfast BT12 6BJ, Northern Ireland, UK

* Corresponding author. Tel: +44 28 9063 4825; fax: +44 28 9031 2907. E-mail address: p.p.mckeown@qub.ac.uk

This editorial refers to ‘Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression’{dagger} by T.G. Neilan et al., on page 1251

The first 10% of the full text of this article appears below.

Anthracycline drugs have been widely used as chemotherapeutic agents against a range of cancers, including sarcomas, carcinomas, leukaemias, and lymphomas. However, cardiotoxic effects, in particular the development of cardiomyopathy, have limited their clinical use. The observation of dose-dependent cardiotoxicity has resulted in a recommended empirical dose limit of 450 mg/m2 of body surface area. Age, gender, pre-existing heart disease, hypertension, and mediastinal irradiation have also been implicated as factors contributing to the development of doxorubicin-associated cardiomyopathy. However, cardiotoxicity may still occur at relatively low levels of drug administration, even in individuals with no additional risk factors, and the onset may be delayed by many years.1 More recently, the use of trastuzumab, a monoclonal antibody directed against the HER2 receptor, has been . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression
Tomas G. Neilan, Davinder S. Jassal, Michael F. Scully, Gang Chen, Catherine Deflandre, Hester McAllister, Elaine Kay, Sandra C. Austin, Elkan F. Halpern, Judy H. Harmey, and Desmond J. Fitzgerald
EHJ 2006 27: 1251-1256. [Abstract] [Full Text]